Firstly, the small sample size and limited external validation due to low incidence of lung adenocarcinoma with ALK-positive and the high proportion of loss to follow-up need to expand the sample size in further investigations to enhance the reliability and generalizability of the study findings, which align with the precious study (58). Here, ALK is linked to lung adenocarcinoma.